Tresperimus: a new agent for transplant tolerance induction

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Tresperimus is a novel agent structurally related to deoxyspergualin (DSG), modified for improved stability.
• DSG and tresperimus demonstrate favorable effects on transplant rejection, unlike DSG's limited antitumour efficacy.
• Traditional immunosuppressants like cyclosporin prevent rejection but do not induce tolerance.

Purpose of the Study:

• To evaluate tresperimus as a novel agent for inducing allogeneic transplant tolerance.
• To compare the effects of tresperimus with traditional immunosuppressants like cyclosporin.
• To elucidate the mechanism of action for tresperimus-induced tolerance.

Main Methods:

• Administration of tresperimus in experimental bone marrow, cardiac, and skin transplant models.
• Assessment of quantitative and qualitative effects on transplant rejection and immune response.
• Investigation of T-cell anergy induction via disruption of T-cell/dendritic cell interaction.

Main Results:

• Tresperimus effectively prevents transplant rejection, inducing donor-specific tolerance without impacting third-party antigen immunity.
• CD4+ T-cells from tresperimus-treated animals can transfer donor-specific tolerance.
• Tresperimus inhibits nuclear localization of NF-kappa B by binding to Hsc70, potentially disrupting T-cell co-stimulation.

Conclusions:

• Tresperimus shows promise as a tolerance-inducing agent, shifting from immunosuppression to tolerance for preventing transplant rejection and graft-versus-host disease.
• The mechanism involves inducing T-cell anergy, likely through Hsc70/NF-kappa B pathway interference.
• Further clinical studies are needed to confirm its role and potential combination therapies.